Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression
View/ Open
Author
Li, Gong-Quan
Guo, Wen-Zhi
Zhang, Yi
Seng, Jing-Jing
Zhang, Hua-Peng
Ma, Xiu-Xian
Zhang, Gong
Li, Jie
Yan, Bing
Tang, Hong-Wei
Li, Shan-Shan
Wang, Li-Dong
Zhang, Shui-Jun
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.18632/oncotarget.6275Metadata
Show full item recordCitation
Li, G., W. Guo, Y. Zhang, J. Seng, H. Zhang, X. Ma, G. Zhang, et al. 2016. “Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.” Oncotarget 7 (3): 2462-2474. doi:10.18632/oncotarget.6275. http://dx.doi.org/10.18632/oncotarget.6275.Abstract
Bromodomain 4 (BRD4) is an epigenetic regulator that, when inhibited, has anti-cancer effects. In this study, we investigated whether BRD4 could be a target for treatment of human hepatocellular carcinoma (HCC). We show that BRD4 is over-expressed in HCC tissues. Suppression of BRD4, either by siRNA or using JQ1, a pharmaceutical BRD4 inhibitor, reduced cell growth and induced apoptosis in HCC cell lines while also slowing HCC xenograft tumor growth in mice. JQ1 treatment induced G1 cell cycle arrest by repressing MYC expression, which led to the up-regulation of CDKN1B (P27). JQ1 also de-repressed expression of the pro-apoptotic BCL2L11 (BIM). Moreover, siRNA knockdown of BIM attenuated JQ1-triggered apoptosis in HCC cells, suggesting an essential role for BIM in mediating JQ1 anti-HCC activity.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823048/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320296
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)